Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials

Reuters03-30

Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials

Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.
Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.
PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.
PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.
Alumis plans to submit a U.S. New Drug Application in second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036386), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2623316344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623316344","market":"us","top_or_hot":-1,"title":"Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.\n        </li>\n<li>\n          Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.\n        </li>\n<li>\n          PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.\n        </li>\n<li>\n          Alumis plans to submit a U.S. New Drug Application in second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036386), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.\n        </li>\n<li>\n          Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.\n        </li>\n<li>\n          PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.\n        </li>\n<li>\n          Alumis plans to submit a U.S. New Drug Application in second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036386), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLccxddQ:1","article_id":"2623316344","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623316344","pubTimestamp":1774865432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.Alumis plans to submit a U.S. New Drug Application in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Sec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ALMS":"Alumis Inc."},"translate_title":"Alumis envudeucitinib在3期银屑病试验第24周达到68%PASI 90","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9},"content_text":"Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials\n    \n\n\n          Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.\n        \n\n          Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.\n        \n\n          PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.\n        \n\n          PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.\n        \n\n          Alumis plans to submit a U.S. New Drug Application in second half of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036386), on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}